Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $20.33 Average Price Target from Brokerages

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $20.3333.

Several equities analysts have recently issued reports on ENTA shares. Westpark Capital raised their price target on shares of Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday, September 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, October 8th. Evercore ISI reduced their price objective on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research report on Monday, September 15th. JPMorgan Chase & Co. initiated coverage on Enanta Pharmaceuticals in a research report on Friday, November 14th. They issued an “overweight” rating and a $17.00 target price for the company. Finally, Jefferies Financial Group upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $14.00 to $20.00 in a report on Wednesday, October 1st.

Enanta Pharmaceuticals Trading Up 1.5%

NASDAQ:ENTA opened at $16.85 on Wednesday. The stock’s 50-day moving average is $13.02 and its 200-day moving average is $9.99. Enanta Pharmaceuticals has a 1-year low of $4.09 and a 1-year high of $17.05. The stock has a market cap of $486.29 million, a P/E ratio of -4.40 and a beta of 0.96.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 17th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.26. Enanta Pharmaceuticals had a negative net margin of 125.36% and a negative return on equity of 93.76%. The business had revenue of $15.13 million during the quarter, compared to analyst estimates of $15.60 million. As a group, equities analysts forecast that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 4,743 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $67,492.89. Following the completion of the sale, the chief executive officer owned 858,026 shares in the company, valued at $12,209,709.98. This represents a 0.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Yat Sun Or sold 2,390 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $34,009.70. Following the transaction, the insider owned 371,392 shares in the company, valued at approximately $5,284,908.16. This trade represents a 0.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 11,961 shares of company stock worth $170,149 in the last quarter. 13.89% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Commodore Capital LP purchased a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at approximately $9,576,000. Millennium Management LLC increased its position in shares of Enanta Pharmaceuticals by 50.2% during the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after purchasing an additional 449,945 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Enanta Pharmaceuticals by 674.7% during the 1st quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock valued at $1,971,000 after purchasing an additional 311,010 shares during the last quarter. Trexquant Investment LP raised its stake in shares of Enanta Pharmaceuticals by 113.4% during the 1st quarter. Trexquant Investment LP now owns 290,059 shares of the biotechnology company’s stock worth $1,601,000 after purchasing an additional 154,105 shares during the period. Finally, PDT Partners LLC boosted its holdings in shares of Enanta Pharmaceuticals by 217.5% in the 1st quarter. PDT Partners LLC now owns 106,200 shares of the biotechnology company’s stock worth $586,000 after buying an additional 72,751 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.